GDD-3898 is under clinical development by Lipidio Pharmaceuticals and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GDD-3898’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GDD-3898 overview

GDD-3898 is under development for the treatment of nonalcoholic fatty liver disease, non-alcoholic steatohepatitis, Prader-Willi syndrome, antipsychotic drug-induced weight gain (AIWG), acne vulgaris and sebaceous hyperplasia. The drug candidate acts by targeting stearoyl-CoA desaturase (SCD-1). It is administered through topical route.

Lipidio Pharmaceuticals overview

Lipidio Pharmaceuticals is a healthcare company that focuses on advancing a molecule to treat diseases associated with excess body fat. It includes non-alcoholic steatohepatitis, Prader-Willi syndrome, and antipsychotic drug-induced weight gain. Lipidio Pharmaceuticals is headquartered in San Diego, California, the US.

For a complete picture of GDD-3898’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.